Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04698915 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
A Phase 2 study, sponsored by Galera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT04698915: Clinical Trial Phase 2 study, sponsored by Galera Therapeutics.
NCT04698915 is a Phase 2 study that was terminated before completion, run by Galera Therapeutics. The registered enrollment target is 177 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04698915, a Phase 2 study, was terminated before completion, sponsored by Galera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic
Primary Outcome
Overall survival is defined as the time from randomization to the date of death from any cause. The number of subjects that have died during this time period is the reported outcome measure.
Interventions
- DRUG Placebo
- DRUG Drug GC4711
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Why NCT04698915 stopped before completion
NCT04698915 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04698915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04698915 about?
NCT04698915 is a clinical study titled "Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer". GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic
What is the current status of trial NCT04698915?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2021-05-07. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04698915?
The interventions under investigation include: Placebo (DRUG), Drug GC4711 (DRUG).
Who is sponsoring clinical trial NCT04698915?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04698915's enrollment target sits among peer trials
177 394th of 2000 higher than 1,607 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI